NCT03726775View on ClinicalTrials.gov

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
HNSCC
Interventions
DRUG

Durvalumab

Infusion of durvalumab during RT and after RT during 6 months

Trial Locations (2)

35042

Centre Eugene Marquis, Rennes

84082

Institut Sainte Catherine, Avignon

All Listed Sponsors
collaborator

UNICANCER

OTHER

collaborator

Center Eugene Marquis

OTHER

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER